bcl2 protein is frequently expressed in LCL and is a strong independent prognostic factor for DFS. p53 expression is related with high tumor burden, but is not an independent risk factor for CR and survival.

Antibody formation in hematologic malignancies is comparable to that in other diseases requiring multiple blood transfusions. Extensive antigen matching before transfusion of patients with hematologic and oncologic malignancies is not necessary and leads to increased costs.

Please be advised that this information was generated on 2018-05-12 and may be subject to change.11 Snyder PJ, Utiger RD. Response to thyrotropin-releasing hormone (TRH) in normal man. J Clin Endocrinol Metab 1972; 34: 380-85. 12 Rooney S, Marino P, Gobrau L, Gross I, Warshaw J. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? M artin den Heijer, Henk J Biom , Wim B J G errits, F rits R Rosendaai, Hans L H aak, P ie rre W W ijerm ans, Gerard M J Bos SummarySeveral studies have shown a relation between » hyperhomocysteinaemia and arterial vascular disease. We looked at the association between hyperhomocysteinaemia and venous thrombosis which could be clinically important as hyperhomocysteinaemia is easily corrected by vitamin supplementation.We studied 185 patients with a history of recurrent venous thrombosis and 220 controls from the general population. Homocysteine concentrations were measured before and 6 h after oral methionine loading. We defined hyperhomocysteinaemia as the homocysteine concentration above the fasting or the postmethionine value found for the 90th percentile of the controls. Of the 185 patients with recurrent thrombosis, 46 (25%) had fasting homocysteine concentrations above the 90th percentile or the controls (odds ratio is 3-1 [1-8-5-5]). After adjustment for age, sex, and menopausal status the odds ratio was 2-0 (l-5-2*7). Similar results were found for the post-methionine value (unadjusted odds ratio 3-1 [1-7-5-5], adjusted 2*6 [1-9-3-5]).Hyperhomocysteinaemia is a common risk factor for recurrent venous thrombosis and can lead to a two-fold or three-fold increase in risk.

In previously untreated elderly patients with AML, MTZ induction therapy produces a slightly better CR rate than does a DNR-containing regimen, but it has no significant effect on remission duration and survival. Ara-C in maintenance may prolong DFS, but it did not improve survival.

About 25 percent of all antibodies became undetectable over the course of time. The antibody screening technique used, rather than the antibody specificity, affected these results. To prevent delayed hemolytic transfusion reactions, precise antibody documentation is of great importance.